이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Brain Connectomic Mechanisms of Spinal Manipulative Therapy on LDH Analgesia Based on Multimodal MRI

Low back and leg pain caused by lumbar disc herniation (LDH) is common. Lever positioning manipulation (LPM) is a spinal manual therapy used to relieve this pain, but how it affects the brain is unclear. This study will compare active LPM with a sham procedure and use multimodal magnetic resonance imaging (MRI) to investigate changes in brain networks associated with pain relief.

A total of 84 adults with LDH will be randomly assigned in a 1:1 ratio to active LPM or sham LPM, with three sessions per week for 12 weeks. An additional 42 age- and sex-matched healthy adults will undergo baseline assessments without treatment. Participants with LDH will be assessed before treatment, immediately after the first session, at week 6, and at week 12. Outcomes include pain intensity, lumbar function, disability, adverse events, and MRI measures of functional and structural brain connectivity. The study aims to identify brain connectomic mechanisms associated with LPM-induced analgesia.

연구 개요

상세 설명

This is a single-center, prospective, randomized, participant- and outcome-assessor-masked, sham-controlled study with a matched healthy control cohort. Eighty-four participants with lumbar disc herniation will be randomly allocated 1:1 to active lever positioning manipulation or sham lever positioning manipulation using a computer-generated block randomization sequence prepared by an independent statistician. Allocation will be concealed in sequentially numbered, opaque, sealed envelopes. Forty-two age- and sex-matched healthy controls will complete baseline clinical and MRI assessments only.

Active and sham treatments will be delivered three times weekly for 12 weeks, with approximately 20 minutes per session. The sham procedure will reproduce the treatment setting, participant position, preparatory procedures, and practitioner contact but will omit the rapid lever-pulling maneuver. Analgesics, neurotrophic drugs, sedatives, spinal manipulation, acupuncture, traction, and other therapies that could affect pain or MRI outcomes will be prohibited during the treatment period.

Participants with LDH will be assessed at baseline before randomization, immediately after the first treatment session, at week 6, and at week 12. The primary outcome is change in pain intensity measured by the Visual Analog Scale from baseline to week 12. Secondary clinical outcomes include lumbar function measured by the Japanese Orthopaedic Association score and disability measured by the Oswestry Disability Index. Multimodal MRI will be used to evaluate longitudinal changes in functional network topology, white-matter structural connectivity, and structure-function coupling. Exploratory analyses will examine gray-matter covariance and associations between clinical improvement and imaging changes. Safety will be assessed through adverse-event monitoring and vital-sign checks at each treatment session.

연구 유형

중재적

등록 (추정된)

126

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310053
        • The Third Affiliated hospital of Zhejiang Chinese Medical University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

Patients with lumbar disc herniation (LDH):

  • Diagnosis of LDH based on clinical symptoms, physical examination findings, and lumbar imaging consistent with neurological localization; central, paracentral, far-lateral, foraminal, or subarticular lumbar disc protrusion.
  • Aged 18-65 years, of either sex, and right-handed.
  • In the non-acute phase of LDH, with symptom duration of more than 2 weeks.
  • Visual Analog Scale (VAS) score greater than 4 and Japanese Orthopaedic Association (JOA) score less than 15.
  • No use of analgesics, neurotrophic drugs, or sedatives within 1 month before enrollment.
  • No systematic treatment, spinal manipulation, or other physical therapies within 1 month before enrollment.
  • Able to understand the study procedures and complete clinical assessments and MRI scans.
  • Provides written informed consent.

Healthy controls:

  • Aged 18-65 years, of either sex, and right-handed.
  • No history of LDH or chronic low back pain.
  • No current pain condition requiring treatment.
  • No neurological or psychiatric disorders.
  • No known structural brain abnormalities.
  • No MRI contraindications.
  • Able to complete clinical assessments and MRI scans.
  • Provides written informed consent.

Exclusion Criteria:

Patients with LDH:

  • Low back pain or sciatica caused by conditions other than LDH.
  • Lumbar spondylolisthesis, lumbar tumor, spinal tuberculosis, severe osteoporosis, or localized lumbar skin lesions that may interfere with treatment.
  • Severe cardiovascular, cerebrovascular, hepatic, renal, hematopoietic, neurological, or psychiatric disease.
  • History of severe head trauma, loss of consciousness, or known structural brain abnormality.
  • Impaired consciousness, severe visual or hearing impairment, speech disorder, or inability to complete clinical assessments.
  • Non-MRI-compatible metal implants, implanted electronic devices, cardiac pacemakers, severe claustrophobia, or inability to tolerate MRI scanning.
  • Asymptomatic LDH.
  • Pregnancy, lactation, or planned pregnancy during the study period.
  • Participation in another clinical trial within the previous 3 months.
  • Any condition judged by the investigators to make the patient unsuitable for participation.

Healthy controls:

  • Any condition that may affect eligibility, MRI safety, or data quality.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Active Lever Positioning Manipulation
Participants with lumbar disc herniation receive active lever positioning manipulation three times per week for 12 weeks, approximately 20 minutes per session. The procedure includes segment localization, stabilization, positioning to the pre-thrust point, and a rapid lever-pulling maneuver during exhalation.
Delivered three times weekly for 12 weeks, approximately 20 minutes per session, by an experienced rehabilitation practitioner. With the participant's hips and knees flexed and legs crossed, the practitioner identifies the target lumbar segment, stabilizes it with the elbow, holds the ankles, and lifts and pulls the legs upward and inward to the pre-thrust position. A rapid lever-pulling maneuver is then performed while the participant exhales.
가짜 비교기: Sham Lever Positioning Manipulation
Participants with lumbar disc herniation receive sham lever positioning manipulation three times per week for 12 weeks, approximately 20 minutes per session. The sham procedure reproduces the treatment setting, position, preparatory procedures, and practitioner contact but omits the rapid lever-pulling maneuver.
Delivered three times weekly for 12 weeks, approximately 20 minutes per session, in the same setting and position as the active procedure. Preparatory positioning and practitioner contact are reproduced, but no rapid lever-pulling maneuver is performed. The position is held for 30 seconds with a 15-cm elastic lumbar belt placed around the lower abdomen and pelvis at L4-S1, light hand contact on the ankles, and gradual release.
간섭 없음: Matched Healthy Controls
Age- and sex-matched healthy adults undergo baseline clinical assessment and multimodal MRI only. They receive no study intervention and provide a reference for baseline brain connectivity measures.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Pain Intensity Measured by the Visual Analog Scale (VAS)
기간: Baseline, immediately after the first treatment session, week 6, and week 12; primary endpoint at week 12
Pain intensity will be assessed using the Visual Analog Scale (VAS). The prespecified primary endpoint is the between-group difference between active LPM and sham LPM in change from baseline to week 12. VAS will also be collected immediately after the first treatment session and at week 6.
Baseline, immediately after the first treatment session, week 6, and week 12; primary endpoint at week 12

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Lumbar Function Measured by the Japanese Orthopaedic Association (JOA) Score
기간: Baseline, immediately after the first treatment session, week 6, and week 12
Lumbar neurological and functional status will be assessed using the Japanese Orthopaedic Association (JOA) score. Change from baseline will be compared between the active LPM and sham LPM groups.
Baseline, immediately after the first treatment session, week 6, and week 12
Change in Disability Measured by the Oswestry Disability Index (ODI)
기간: Baseline, immediately after the first treatment session, week 6, and week 12
Disability related to low back pain will be assessed using the Oswestry Disability Index (ODI), a patient-reported measure of limitations in daily activities. Change from baseline will be compared between the active LPM and sham LPM groups.
Baseline, immediately after the first treatment session, week 6, and week 12
Change in Resting-State Functional Brain Network Topology
기간: Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12
Resting-state functional MRI will be parcellated using the 116-region Automated Anatomical Labeling atlas. Pearson correlation matrices and graph-theoretical metrics reflecting network integration, segregation, and nodal importance will quantify functional topology. Longitudinal change will be compared between active LPM and sham LPM.
Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12
Change in White-Matter Structural Connectivity
기간: Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12
Diffusion tensor imaging will be parcellated with the 116-region Automated Anatomical Labeling atlas. Whole-brain deterministic streamline tractography will generate structural networks. Edges will be weighted by mean fractional anisotropy along streamlines connecting region pairs, with absent connections coded as zero. Longitudinal change will be compared between active LPM and sham LPM.
Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12
Change in Brain Structure-Function Coupling
기간: Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12
Functional and white-matter structural connectivity matrices will use the same 116-region Automated Anatomical Labeling parcellation. For each participant, structure-function coupling will be quantified by the correspondence between functional and structural edge weights across the connectome. Longitudinal change will be compared between active LPM and sham LPM.
Baseline, immediately after the first treatment session, week 6, and week 12; main longitudinal comparison from baseline to week 12

기타 결과 측정

결과 측정
측정값 설명
기간
Change in Group-Level Gray-Matter Structural Covariance Networks
기간: Baseline, immediately after the first treatment session, week 6, and week 12; exploratory longitudinal comparison from baseline to week 12
High-resolution T1-weighted images will be segmented, and gray-matter volume will be extracted for each Automated Anatomical Labeling region. Group-level structural covariance networks will be constructed from interregional covariance in gray-matter volume after adjustment for relevant demographic and anatomical covariates. This exploratory measure will be interpreted at the group level rather than as an individual biomarker.
Baseline, immediately after the first treatment session, week 6, and week 12; exploratory longitudinal comparison from baseline to week 12
Association Between Changes in Connectome Metrics and Clinical Outcomes
기간: Baseline through week 12; change scores for the main exploratory association calculated from baseline to week 12
Exploratory Spearman rank correlation analyses will assess whether changes in individual-level functional network topology, white-matter structural connectivity, and structure-function coupling are associated with changes in Visual Analog Scale, Japanese Orthopaedic Association, and Oswestry Disability Index scores. The Benjamini-Hochberg false discovery rate procedure will control for multiple comparisons.
Baseline through week 12; change scores for the main exploratory association calculated from baseline to week 12
Incidence of Adverse Events
기간: From the first treatment session through the end of the 12-week intervention
The number and proportion of participants experiencing adverse events will be recorded. Any undesirable medical occurrence will be documented regardless of causal relationship, and severity and relationship to the intervention will be assessed. Vital signs and treatment-related discomfort or safety concerns will be checked at each treatment session; serious adverse events will be reported according to institutional requirements.
From the first treatment session through the end of the 12-week intervention

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2027년 9월 1일

연구 등록 날짜

최초 제출

2026년 7월 22일

QC 기준을 충족하는 최초 제출

2026년 7월 22일

처음 게시됨 (실제)

2026년 7월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 27일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 22일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다